UNITED STATES

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): July 24, 2007

                            Anika Therapeutics, Inc.
             (Exact name of registrant as specified in its charter)

        Massachusetts                   000-21326               04-314-5961
(State or other jurisdiction of    Commission file number     (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                     160 New Boston Street, Woburn, MA 01801
               (Address of principal executive offices) (Zip code)

        Registrant's telephone number, including area code: 781-932-6616

          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


                        Section 2--Financial Information

Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibit attached hereto, is intended to
be furnished and shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.

On July 24, 2007, Anika Therapeutics, Inc. issued a press release announcing its
financial results for the second quarter and six months ended June 30, 2007. The
full text of the press release is furnished as Exhibit 99.1 hereto and is
incorporated herein by reference.

                  Section 9--Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1    Press Release of Anika Therapeutics, Inc. dated July 24, 2007.

                  [Remainder of page left blank intentionally]


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be filed on its behalf by the
undersigned hereunto duly authorized.

                                        Anika Therapeutics, Inc.

Dated: July 24, 2007                    By: /s/ Kevin W. Quinlan
                                            Kevin W. Quinlan
                                            Chief Financial Officer

                                  Exhibit Index

99.1    Press Release of Anika Therapeutics, Inc. dated July 24, 2007 .